An Assessment of the Screening Method to Evaluate Vaccine Effectiveness: The Case of 7-Valent Pneumococcal Conjugate Vaccine in the United States
Open Access
- 1 August 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (8), e41785
- https://doi.org/10.1371/journal.pone.0041785
Abstract
The screening method, which employs readily available data, is an inexpensive and quick means of estimating vaccine effectiveness (VE). We compared estimates of effectiveness of heptavalent pneumococcal conjugate vaccine (PCV7) against invasive pneumococcal disease (IPD) using the screening and case-control methods. Cases were children aged 19–35 months with pneumococcus isolated from normally sterile sites residing in Active Bacterial Core surveillance areas in the United States. Case-control VE was estimated for 2001–2004 by comparing the odds of vaccination among cases and community controls. Screening-method VE for 2001–2009 was estimated by comparing the proportion of cases vaccinated to National Immunization Survey-derived coverage among the general population. To evaluate the plausibility of screening-method VE findings, we estimated attack rates among vaccinated and unvaccinated persons. We identified 1,154 children with IPD. Annual population PCV7 coverage with ≥1 dose increased from 38% to 97%. Case-control VE for ≥1 dose was estimated as 75% against all-serotype IPD (annual range: 35–83%) and 91% for PCV7-type IPD (annual range: 65–100%). By the screening method, the overall VE was 86% for ≥1 dose (annual range: −240–70%) against all-serotype IPD and 94% (annual range: 62–97%) against PCV7-type IPD. As cases of PCV7-type IPD declined during 2001–2005, estimated attack rates for all-serotype IPD among vaccinated and unvaccinated individuals became less consistent than what would be expected with the estimated effectiveness of PCV7. The screening method yields estimates of VE that are highly dependent on the time period during which it is used and the choice of outcome. The method should be used cautiously to evaluate VE of PCVs.This publication has 18 references indexed in Scilit:
- Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of ageEmergencias, 2009
- Measles outbreak in South Africa, 2003-2005.2009
- Pneumococcal conjugate vaccine for childhood immunization--WHO position paper.2007
- Vaccine Effectiveness Estimates, 2004–2005 Mumps Outbreak, EnglandEmerging Infectious Diseases, 2007
- Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control studyThe Lancet, 2006
- Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introductionThe Lancet, 2004
- EstimatingHaemophilus influenzaeType b Vaccine Effectiveness in England and Wales by Use of the Screening MethodThe Journal of Infectious Diseases, 2003
- Effectiveness of the pertussis vaccination program as determined by use of the screening method: United States, 1992-1994.The Journal of Infectious Diseases, 1997
- Estimation of Vaccine Effectiveness Using the Screening MethodInternational Journal of Epidemiology, 1993
- Field evaluation of vaccine efficacy.1985